Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 13Carcinoma, Renal Cell 6Tuberous Sclerosis 5Neoplasm Metastasis 5Hodgkin Disease 5Glioblastoma 5Colorectal Neoplasms 5Central Nervous System Neoplasms 5Waldenstrom Macroglobulinemia 4Stomach Neoplasms 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Pancreatic Neoplasms 4Lymphoma, Mantle-Cell 4Head and Neck Neoplasms 4Gliosarcoma 4Triple Negative Breast Neoplasms 3Squamous Cell Carcinoma of Head and Neck 3Sezary Syndrome 3Recurrence 3Prostatic Neoplasms 3Neoplasms 3Mycosis Fungoides 3Lymphoma, T-Cell, Cutaneous 3Lymphoma, Large-Cell, Anaplastic 3Lymphoma, Large B-Cell, Diffuse 3Lymphoma, Follicular 3Lymphoma, B-Cell, Marginal Zone 3Leukemia, Lymphocytic, Chronic, B-Cell 3Leukemia 3Kidney Neoplasms 3

Interventions

Temozolomide 1Sulfasalazine 1Sirolimus 1Radiotherapy 1Memantine 1Gabapentin 1Everolimus 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Epilepsy × Everolimus × Clear all
NCT01070316 2017-03-13

Everolimus (RAD001) Therapy for Epilepsy in Patients With Tuberous Sclerosis Complex (TSC)

Children's Hospital Medical Center, Cincinnati

Phase 1/2 Completed
20 enrolled 8 charts

Epilepsy, Hereditary Sensory and Autonomic Neuropathies, Tuberous Sclerosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡